Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $9M (up 565.6% year over year) with net income of −$17M.
Q1 2026 key financials · XBRL
- Revenue
- $9M
- +565.6% YoY
- Net income
- −$17M
- −41.9% YoY
- Operating margin
- -264.1%
- EPS (diluted)
- −$0.30
- −25.0% YoY
Source: XBRL data from the ABEONA THERAPEUTICS INC. (ABEO) Q1 2026 10-Q on SEC EDGAR. USD.
ABEONA THERAPEUTICS INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $8.7M vs $0 YoY, driven by commercial ZEVASKYN sales
- Gross margin 69.1%, based on $8.7M revenue and $2.7M cost of sales
- Best-performing product ZEVASKYN, generating $8.7M quarterly revenue
- Operating loss $23.0M vs $19.7M YoY; operating margin (264.1%) vs not applicable
- Cash resources $168.3M; operating cash outflow $19.8M vs $18.4M YoY
- Outlook: funding expected through at least next 12 months; additional financing may be needed
Risk Factors
- No Risk Factors section provided; submitted text begins with Item 5, Other Information
- CFO Rule 10b5-1 arrangement covering 99,036 restricted-stock-award shares through April 26, 2027
- Director Eric Crombez Rule 10b5-1 arrangement covering up to 63,456 shares through May 7, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ABEONA THERAPEUTICS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.